Tau aids selection of anti-amyloid drug recipients

Owing to the high costs, potential risks and modest efficacy of anti-amyloid therapies for Alzheimer disease, the ability to identify people who will derive the greatest benefit from these drugs is vital. A study published in JAMA Neurology has found that plasma p-tau217 measurements can be used to assess both the likelihood of amyloid-β pathology and the severity of tau pathology. These measurements could provide a valuable pre-screening tool for patients with cognitive impairment who are potential candidates for anti-amyloid drug treatment.